Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

15.28 +0.31 (+2.07%)
Streaming Delayed Price Updated: 3:55 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
News headline image
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024 ↗
Summit Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Stock Crushed the Market This Week ↗
The company was a standout in the biotech field, rising by nearly 23% over the period. 
Via The Motley Fool
News headline image
Akeso Marks Profit Milestone With Swift Rights Issue ↗
Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The next highly anticipated product in the firm’s drug pipeline is ivonescimab, the... 
Via Benzinga
News headline image
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment ↗
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in... 
Via Benzinga
News headline image
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of... 
Via Benzinga
News headline image
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
Via Benzinga
News headline image
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
News headline image
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The... 
Via Benzinga
Topics Stocks
News headline image
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 100 Points; US Leading Economic Index Falls In January ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Summit Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
Chart Of The Day: Summit Therapeutics Begins To Soar ↗
Summit Therapeutics Inc., a biopharmaceutical company, researches and develops primarily oncology therapies in the United States and the United Kingdom. 
Via Talk Markets
News headline image
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.